We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
TFS Financial
TFSL
$5.14B
| $757K | ﹤0.01% |
38,468
+1,808
| +5% | +$34.9K |
|
2202
Applied Optoelectronics
AAOI
$10.3B
| $756K | ﹤0.01% |
63,641
+3,168
| +5% | +$33.8K |
|
|
LTRPA
2203
DELISTED
Liberty TripAdvisor Holdings, Inc. Series A
LTRPA
| $756K | ﹤0.01% |
102,919
+479
| +0.5% | +$3.85K |
|
2204
MacroGenics
MGNX
$248M
| $755K | ﹤0.01% |
69,386
+1,104
| +2% | +$10.9K |
|
2205
Daktronics
DAKT
$1.06B
| $754K | ﹤0.01% |
123,741
+2,822
| +2% | +$18.9K |
|
2206
Johnson Outdoors
JOUT
$506M
| $752K | ﹤0.01% |
9,810
+508
| +5% | +$33.2K |
|
2207
First Mid Bancshares
FMBH
$1.39B
| $751K | ﹤0.01% |
21,307
-22
| -0.1% | -$769 |
|
|
LGTY
2208
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
| $751K | ﹤0.01% |
50,473
+380
| +0.8% | +$5.97K |
|
2209
Rhythm Pharmaceuticals
RYTM
$7.62B
| $744K | ﹤0.01% |
32,395
+6,542
| +25% | +$145K |
|
2210
Bristow Group
VTOL
$1.31B
| $743K | ﹤0.01% |
36,510
-2,138
| -6% | -$42.4K |
|
2211
Costamare
CMRE
$1.77B
| $738K | ﹤0.01% |
77,450
+436
| +0.6% | +$3.48K |
|
|
ALTA
2212
DELISTED
Altabancorp
ALTA
| $738K | ﹤0.01% |
24,489
-107
| -0.4% | -$3.14K |
|
2213
CNB Financial Corp
CCNE
$1.05B
| $737K | ﹤0.01% |
22,554
-109
| -0.5% | -$3.41K |
|
2214
Upwork
UPWK
$1.18B
| $735K | ﹤0.01% |
68,864
+2,577
| +4% | +$32.5K |
|
2215
Option Care Health
OPCH
$3.55B
| $733K | ﹤0.01% |
49,133
+228
| +0.5% | +$3.08K |
|
2216
Assembly Biosciences
ASMB
$526M
| $731K | ﹤0.01% |
2,977
+65
| +2% | +$12K |
|
2217
Waterstone Financial
WSBF
$377M
| $731K | ﹤0.01% |
38,421
+466
| +1% | +$8.58K |
|
2218
PagerDuty
PD
$865M
| $730K | ﹤0.01% |
31,223
+21,622
| +225% | +$532K |
|
2219
TherapeuticsMD
TXMD
$24M
| $730K | ﹤0.01% |
6,033
+289
| +5% | +$41.6K |
|
2220
Winmark
WINA
$1.3B
| $730K | ﹤0.01% |
3,682
-18
| -0.5% | -$3.25K |
|
2221
Carter Bankshares
CARE
$778M
| $727K | ﹤0.01% |
30,663
+895
| +3% | +$18.5K |
|
2222
Equity Bancshares
EQBK
$1.06B
| $716K | ﹤0.01% |
23,195
+200
| +0.9% | +$5.72K |
|
2223
ADT
ADT
$5.63B
| $715K | ﹤0.01% |
90,106
+489
| +0.5% | +$3.86K |
|
|
GTS
2224
DELISTED
Triple-S Management Corporation
GTS
| $710K | ﹤0.01% |
38,416
+1,795
| +5% | +$30.6K |
|
2225
Amneal Pharmaceuticals
AMRX
$5.89B
| $709K | ﹤0.01% |
147,019
+16,872
| +13% | +$58.6K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.